published a paper that discusses the recent advances in biocatalysis, and the impact it is having on the commercial development of biofuels, renewable chemicals, and pharmaceutical products. The paper was published by researchers at Codexis, Inc. (Nasdaq:CDXS), Emory University, Greifswald University, Lonza AG, Merck, and Seoul National University. The team identified directed evolution as a key component of the third wave in biocatalysis. Dr. Gjalt Huisman, Vice President, Product Planning, Codexis Pharmaceuticals was a coauthor on this paper.
Directed evolution forms the foundation of Codexis’ CodeEvolver™ technology platform and has enabled the company to develop processes based on custom enzymes, or biocatalysts, to replace traditional chemical synthesis in the industrial manufacturing of pharmaceutical compounds. The paper specifically highlights rapid progress in directed evolution, DNA sequencing, and gene synthesis as the key advancements made in directed evolution.
In directed evolution, researchers customize natural enzymes through genetic mutation, enabling the creation of new enzymes to perform specific tasks at industrial scale. The technology is used worldwide to create more efficient, cleaner biological manufacturing processes for the chemical and pharmaceutical industries.
As the paper reports, “Over the last 10 years, scientific and technological advances have established biocatalysis as a practical and environmentally friendly alternative to traditional metallo- and organo-catalysts in chemical synthesis, both at the bench and the industrial scale. [These] novel enzymes are needed today to convert biomass into second and third generation biofuels, [and] into materials and chemicals.”
“Codexis is proud to be at the forefront of the advancements made in directed evolution with our CodeEvolver™ directed evolution technology platform,” said David Anton, Ph.D., Codexis Chief Technology Officer. “Publication of these developments reaffirms the merit of our 10-year effort to broaden and commercialize this technology platform. Our scientists have achieved numerous milestones in improved function over natural enzymes, including a 4,000-fold improvement of an enzyme for manufacture of an intermediate to atorvastatin (Nature Biotechnol. 2007, 25:338), a 27,000-fold improvement for an enzyme for manufacture of sitagliptin with Merck (Science
2010, 329:305), and a more than 2-million-fold improvement in an enzyme for carbon capture. Today, we are deploying the most advanced directed evolution technologies to generate biocatalysts for application through global partnerships in the biofuels, bio-based chemicals, and pharmaceutical industries.”
The paper can be found online at
About Codexis, Inc.
Codexis, Inc. is a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates. Codexis’ product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol. Partners and customers include global leaders such as Shell, Merck and Pfizer. For more information, see
Codexis Forward-Looking Statements
This press release contains forward-looking statements relating to the application of our technologies in multiple fields. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and could materially affect actual results. Factors that could materially affect actual results include that we are dependent on a limited number of products in our pharmaceutical business, our dependence on contract manufacturers for commercial scale production of our enzymes. our customers’ pharmaceutical products may not be well received in the market. Additional factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K for the period ended December 31, 2011 filed with the Securities and Exchange Commission on March 5, 2012, including under the caption “Risk Factors.” Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.